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Summary Proliferative activities in 181 primary Borrmann type 4 gastric carcinomas were investigated using
percentage labelling of proliferating cell nuclear antigen (PCNA) and an argyrophilic nucleolar organiser
region (AgNOR) count. Tumours with a high proliferative activity often metastasised to lymph nodes
(P<0.01), and these patients had a lower survival rate (P<0.05). A significant correlation was recognised
between the PCNA labelling percentage and AgNOR count (r = 0.452, P< 0.001). Cox's regression analysis
showed that PCNA labelling percentage is an independent prognostic factor. These results indicate that
estimating proliferative activity may be useful in predicting lymph node metastasis and patients' prognosis in
cases of Borrmann type 4 gastric carcinoma.
Advanced carcinoma of the stomach can be classified based
on Borrmann's criteria into one of four types (1-4) (Borr-
mann, 1926). A knowledge of this classification is important
for endoscopists, radiologists and surgeons (Borchard, 1990).
Of the Borrmann types of carcinomas, type 4 is a diffuse
malignant lesion with indistinct borders, and is usually
identified only at a very advanced stage (Maehara et al.,
1992a). The lack of sharp borders can lead to underestima-
tion of the size. As these cancers grow in the plane of the
submucosa beneath an otherwise normal mucosa, estab-
lishing the histological diagnosis is difficult (Borchad, 1990).
The clinical course is usually unfavourable and the 5 year
survival rates are only 0-20% (Furukawa et al., 1988;
Maehara et al., 1992a). Though many investigators have
studied this entity from various aspects, the biological char-
acteristics of Borrmann type 4 gastric carcinoma remain an
open question.
As it is now feasible to measure proliferative activities of
cells in formalin-fixed paraffin-embedded sections of surgical
samples, two parameters of proliferative activity, pro-
liferating cell nuclear antigen (PCNA) and argyrophilic
nucleolar organiser regions (AgNOR), were measured.
PCNA, a 36 kDa non-histone nuclear polypeptide, is an
auxiliary protein of DNA polymerase delta (Bravo et al.,
1987), and plays a critical role in the initiation of cell pro-
liferation (Jaskulski et al., 1988). The levels of PCNA in-
crease in the nucleus during the late GI phase immediately
prior to the onset of DNA synthesis, become maximal during
the S phase, decline again during G2 and are low in M phase
and quiescent cells (Kurki et al., 1987). Though PCNA stain-
ing has limitations in that the molecule has a long half-life
which can also lead to staining of cells which have exited
from the cycle (Bravo & Bravo, 1987), it is a useful marker
for proliferating cells (McCormick & Hall, 1992). Nucleolar
organiser regions (NORs) are loops of DNA (rDNA) encoded
for ribosomal RNA (rRNA) production (Watson et al.,
1987). The proteins associated with the NORs, the so-called
AgNOR proteins, are argyrophilic, acidic and non-histone
(Fakan & Hernandez-Verdan, 1986) and may serve as a
marker for rDNA transcription activity or of rDNA trans-
criptional potential (Dimova et al., 1982; Busch, 1984;
Walker, 1988). Thus, AgNOR staining can also serve as a
parameter of proliferation (Egan & Crocker, 1992).
We examined the relationship between these two para-
meters and clinicopathological factors of gastric carcinomas.
The objective of this study was to clarify the proliferative
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activity of Borrmann type 4 gastric carcinoma, with regard to
clinical prognosis.
Materials and methods
Patients
The 181 Japanese patients with primary Borrmann type 4
gastric cancer studied herein had undergone gastrectomy in
the National Kyushu Cancer Center, Fukuoka, Japan, from
1972 to 1990. Partial gastrectomy was done in 43 patients
and total gastrectomy with lymph node dissection in 138. A
thorough histological examination was made on haematox-
ylin and eosin-stained preparations, and the histological
classification was according to the tumour-node-metastasis
classification system of the International Union Against
Cancer (UICC, 1987). Macroscopic subtype, giant fold type,
stenotic type and eroded type were classified according to
Iwanaga et al. (1983). Adjuvant chemotherapy was given to
171 patients.
Immunohistochemical studyfor PCNA
Sections from paraffin blocks were dewaxed and stained
using the avidin-biotin-peroxidase complex method. The
primary antibody, PC10, a monoclonal mouse antibody for
human PCNA, was purchased from Dako (Carpinteria, CA,
USA). The sections were incubated for 2 h with PC1O (dilu-
tion 1:20) at room temperature, with biotinylated goat anti-
mouse IgG (1:200 for 30 min; Vector Laboratories), and with
the avidin-biotin-peroxidase complex (for 30min; Vector
Laboratories). Peroxidase labelling was developed with 3,3'-
diaminobenzidine and hydrogen peroxide, and the sections
were counterstained with Mayer's haematoxylin.
To ensure consistency of PCNA staining between batches,
a known positive control gastric carcinoma was included in
each round. Negative controls were included by performing
duplicate assays, in one of which the primary antibody was
replaced by phosphate-buffered saline.
All of the nuclei stained were regarded as positive for
PCNA (Figure la). The percentage PCNA labelling was
determined by observing 1,000 nuclei in areas of the section
with the highest labelling, and the percentage of PCNA-
labelfed nuclei was used for analysis. The principal method
for determination of heterogeneity was as follows: (1) the
entire area of each section was observed with low-power
magnification (x 20) to determine the area where the cells
positive for PCNA had gathered most densely, and (2) the
counting ofPCNA-positive cells was done in this area, under
conditions of high-power magnification (x 400).
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Figure 1 a, Gastric carcinoma of moderately differentiated type
stained with PC1O antibody and showing nuclei expressing
PCNA ( x 400). b, Scattered AgNORs were stained in the nuclei
of poorly differentiated adenocarcinoma ( x 1,000).
AgNOR staining
From the complete group of 181 patients, 174 tissues were
also examined using AgNOR staining. The one-step silver
colloid method was used. The NOR staining solution was
prepared according to the description of Ploton et al. (1982).
A mixture of one volume of 2% gelatin in 1% formic acid
and two volumes of a 50% silver nitrate solution was poured
over the sections and the preparations were left for 1 h at
room temperature in the dark. On the AgNOR-stained slides,
careful focusing made visible the AgNORs in the nucleus, in
the form of black dots (Figure lb). At a magnification of
x 1,000 (oil immersion) all dots, both satellite and those
within clusters, were counted. One hundred cells from each
lesion were analysed and a mean score ofAgNOR count was
recorded.
Statistical analysis
Clinicopathological data were stored in an IBM 4381 main-
frame computer. The Biomedical Computer Program (BMDP)
was used for all statistical analyses (Dixon, 1988). The
BMDP P4F and P3S programs were used for the chi-square
test and the Mann-Whitney test to compare characteristics
between high and low groups with individual proliferative
activities. Linear regression analyses were used to determine
the correlation between the percentage PCNA labelling and
the AgNOR count. Quantitative data on PCNA and AgNOR
were compared using Student's t-test. The BMDP PIL pro-
gram was used to analyse survival by the Kaplan-Meier
method, and to compare survival curves, by the method of
Mantel and Cox. The BMDP P2L program was used for
a multivariate adjustment of all covariates, simultaneously,
using the Cox regression analysis (Cox, 1972).
Results
Proliferative activity and clinicopathological characteristics
PCIO immunostaining was almost entirely confined to the
nucleus, and was diffuse, granular or a mixture of both. The
distribution of PC10-positive cells was not homogeneous in
many cases, and varied in different areas of even the same
tumour. PC10-positive cells were frequently present in the
advancing margin of the tumour, therefore counting was
done in this area.
The PCNA labelling index varied from 9.8% to 85.4%.
The mean was 36.5%. The cases were divided into two
groups: a high labelling group (>36.5) and a low labelling
group (<36.5). Table I summarises the clinicopathological
characteristics of the high and low PCNA labelling groups.
Tumours with a high PCNA percentage of labelling were
associated with a higher incidence of lymphatic permeation,
venous invasion and metastasis to lymph nodes than were
those with low PCNA labelling (P<0.01). The percentage
PCNA labelling was not related to the sex, age, tumour size,
macroscopic subtype, depth of invasion, histological type,
peritoneal dissemination, liver metastasis or operative
curability.
As for AgNOR staining, the result was much the same as
PCNA staining. AgNOR counts varied from 1.89 to 5.88,
and the mean was 3.58. Tumours with high proliferative
Eactivity (>3.58) were more likely to invade lymphatics, veins
and lymph nodes than were those with low proliferative
activity (<3.58).
Figure 2 shows the results of linear regression analysis of
percentage PCNA labelling and AgNOR count in primary
gastric tumours. There was a significant correlation between
the percentage PCNA labelling and the AgNOR count
(r = 0.452, P<0.001).
Proliferating activity andprognosis
Survival curves for patients with carcinomas in the low and
high PCNA labelling groups are shown in Figure 3. Surgical
mortality was excluded in the analysis of survival. In patients
with tumours with a high percentage of PCNA labelling
survival rates were less favourable than in those with
tumours with low labelling (P<0.001).
Of the 181 patients, 28 who underwent curative operation
died within 18 months, and 22 patients lived for over 3 years.
Table II shows the mean proliferative activities of these two
groups. Tumours in patients who died within 18 months had
a significantly higher percentage of PCNA labelling and
higher AgNOR count than did those from patients who lived
for over 3 years (P<0.05).
To search for an independent prognostic factor of Borr-
mann type 4 carcinoma, we carried out a multivariate Cox
regression analysis. Factors examined included the sex, age,
tumour size, macroscopic subtype, peritoneal dissemination,
liver metastasis, lymph node metastasis, histological type,
depth of invasion, surgical method, operative curability,
adjuvant chemotherapy, percentage PCNA labelling,
AgNOR count and the period of diagnosis (time trends).
Multivariate analysis revealed that tumour size, gross
appearance, operative curability and percentage PCNA label-
ling were independent prognostic factors of Borrmann type 4
gastric carcinoma (Table III).
Discussion
The results of clinical treatment of patients with Borrmann
type 4 gastric carcinoma remain poor. The associated lymph
node metastasis, invasion into neighbouring structures and
peritoneal dissemination present a great challenge for medicalPROLIFERATIVE ACTIVITY IN GASTRIC CANCER 751
Table I Histological findings and proliferative activity
PCNA labelling (%) AgNORs count
Histological findings <36.5 >36.5 <3.58 >3.58
Sex
Male
Female
Mean age (years)
Tumour size (cm) (mean ± s.d.)
Macroscopic subtye
Giant fold
Stenotic
Eroded
Histological type
Well-differentiated
Moderately differentiated
Poorly differentiated
Signet
Mucinous
Other
Tumour extension
pT2
pT3
pT4
Invasion into lymphatics
No invasion
Slight invasion
Moderate invasion
Severe invasion
Venous invasion
No invasion
Slight invasion
Moderate invasion
Severe invasion
Lymph node involvement
pNO
pNl
pN2
pMI
Peritoneal dissemination
Negative
Positive
Metastasis to the liver
Negative
Positive
Stage
IA
IB
II
IIIA
IIIB
IV
Curability
Curable
Non-curable
Total
*P<0.05, **P<0.01.
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Figure 2 Correlation between PCNA labelling (I
count in Borrmann type 4 gastric carcin
r = 0.0452, P<0.001).
care (Furukawa et al., 1988). Our previous data (Mori et al.,
1993) showed that the mean percentage of PCNA labelling of
* Borrmann types 3 and 4 gastric carcinoma was 37.6% and
that of Borrmann types 1 and 2 was 30.2%. The proliferative
activity of invasive type carcinoma (types 3 and 4) was
significantly higher than that of localised lesions (types 1 and
* 2) (P<0.01). Between types 3 and 4, there is only a slight
differences; thus, the proliferative activity of Borrmann type
4 was somewhat higher than that of other types of gastric
5 6 carcinoma. Kamel et al. (1981) reported that the mitosis
index of scirrhous-type gastric carcinoma was lower than that
of the medullary type. Excavated lesions of early carcinoma
%) and AgNOR of the stomach are thought to progress to Borrmann type 4
oma. (n = 174, in the advanced stages (Nagayo & Yokoyama, 1974; Sugano
et al., 1982). Nakamura et al. (1980) stated that 3-8 years is
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Figure 3 The survival curves of patients with Borrmann type 4
gastric carcinoma. The thin black line indicates cases with low
proliferative activity (PCNA labelling <36.5%) and the bold
black line indicates those with high proliferative activity
(>36.5%). There was a significant difference (P<0.001).
the mean peiod from the earliest recognisable lesions of
gastric carcinomas to advanced scirrhous carcinoma. The
rapid intramural invasiveness and the late detection of Borr-
mann type 4 carcinoma in the advanced stage may account
for the bad prognosis.
Even among patients with the same Borrmann type 4
carcinoma, there are variations in lifespan. Our investigation
had revealed that patients with Borrmann type 4 gastric
carcinoma of high proliferative activity had a poorer prog-
nosis than did those with carcinoma of low proliferative
activity. We previously reported that gastric carcinoma with
high proliferative activity often metastasised to lymph nodes
(Kakeji et al., 1991). The same trend was recognised even
when the study was restricted to Borrmann type 4 carcinoma,
and for patients with tumours of high proliferative activity
the prognosis was poor. There was a significant relationship
between PCNA labelling and AgNOR count; hence these two
parameters are probably interdependent. As both factors
stain easily and paraffin-embedded tissue sections can be
used, either is likely to lead to a better understanding of the
proliferative activity of cancer cells.
Lymph node involvement, serosal invasion, peritoneal
metastasis and macroscopic subtype have been considered
useful prognostic indicators of Borrmann type 4 gastric car-
cinomas (Nagayo et al., 1974; Furukawa et al., 1988). In the
current multivariate analysis, tumour size, macroscopic sub-
type, operative curability and percentage PCNA labelling
were independent factors associated with the prognosis. Pro-
Table II Proliferative activity of tumours with poor and with good
prognoses
Patients PCNA labelling (%) AgNOR count
Died within 18 months 39.3 ± 16.8 * 3.68 ± 0.92 *
(n = 28)
Lived for over 3 years 29.7 10.5 3.18 0.73)
(n = 22)
*P<0.05.
Table III Cox regression analysis of Borrmann type 4 gastric
cancer
Prognostic factors Regression
(observed value) coefficient P-value
Tumour size (cm) 0.080 <0.01
Macroscopic subtype (giant fold, - 0.382 <0.01
stenotic, eroded)
Operative curability 0.754 <0.01
(curative, non-curative)
PCNA labelling (%) 0.019 <0.05
liferative activity is one of the independent prognostic factors
of Borrmann type 4 carcinoma. As for macroscopic subtype,
Sowa et al. (1989) found that extensive lymphatic spread was
more often recognised in those tumours with giant folds than
those without such folds. Iwanaga et al. (1983) found that
giant fold type or stenotic type gradually extended to adja-
cent organs or to the peritoneum, and that the eroded type
invaded via lymphatic vessels in a rather short time. In our
study, though patients with giant fold-type carcinoma died
earlier than those with the eroded type, there was no
significant difference in proliferative activity among these
macroscopic subtypes. We consider that proliferative activity
is an objective factor to predict survival of a patient.
By estimating the proliferative activity, the physician can
estimate the extent of lymph node metastasis and the prog-
nosis, and can tailor post-operative adjuvant chemotherapy
for individual patients. For patients with carcinoma ofa high
proliferative activity, aggressive adjuvant chemotherapy is the
policy in our clinics.
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